Unlock instant, AI-driven research and patent intelligence for your innovation.

Medicinal composition

A composition and drug technology, which is applied in the direction of pharmaceutical formulation, dispersion liquid delivery, organic active ingredients, etc., can solve the problem of reducing bitterness, etc., and achieve the effect of inhibiting the decline of dissolution and excellent dissolution stability

Active Publication Date: 2021-11-19
ASTELLAS PHARMA INC
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, for example, when the tablet is suspended in a small amount of water, the effect of dissolving the drug and reducing the bitterness disappears, so there is room for further improvement

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition
  • Medicinal composition
  • Medicinal composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0117] The hemifumarate of geritinib described in the present examples and the like used was produced by the method described in Patent Document 1 (International Publication No. 2010 / 128659) or a method based thereon.

[0118] PEARLITOL (registered trademark) 50C (manufactured by ROQUETTE) was used for mannitol described in this example, Sucralose (registered trademark) (P) (manufactured by Saneigen FFI) was used for sucralose, and aspartame Ajinomoto KK Aspartame (manufactured by Ajinomoto), HPC L (manufactured by Nippon Soda) (hereinafter sometimes referred to as HPC) is used for hydroxypropyl cellulose, and isomalt hydrate is used GalenIQ 721 (manufactured by BENEO-PALATINIT), sweet peral (registered trademark) P200 (manufactured by ROQUETTE) was used for maltitol, NEOSORB (registered trademark) XTAB 290 (manufactured by ROQUETTE) was used for sorbitol, refined white sugar (UE -E) (manufactured by Kanto Chemical Industry), Trehalose (P) (manufactured by Asahi Kasei) was use...

Embodiment 1

[0130] "Manufacture of the tablet of Example 1"

[0131] 2.21 kg of geritinib hemifumarate, 2122.0 g of mannitol, and 1680.0 g of sucralose were mixed using a fluidized bed granulator (GPCG-PRO-5, manufactured by Powrec) according to the formulation described in Table 1 3602 g (solid content: 20 weight%) of isomalt hydrate aqueous solution was sprayed and granulated as a binder liquid, and it dried and obtained the granulated product. After sieving to remove aggregates, weigh 5385.6 g from 6377.5 g of the obtained granulated product, add 288.0 g of L-HPC and 115.2 g of Mg-St, and use a mixer (Contenamikiser PM200 (60 L container), Hiroshima Metal & Machinari-manufactured) were mixed to obtain a mixture. The obtained mixture was tableted with a rotary tablet machine (HT-CVX-TYPEIII20, manufactured by Hata Tekko) to obtain plain tablets. 900.6 g of the obtained plain tablet was added to a film coating machine (HCT-30, manufactured by Floint Industrial Co., Ltd.), and film-coat...

Embodiment 2

[0132] "Manufacture of the tablet of Example 2"

[0133] According to the formula recorded in Table 1, 165.75 g of geritinib hemifumarate, 186.15 g of mannitol, and 126.0 g of sucralose were granulated with a fluidized bed granulator (GPCG-1, manufactured by Powrec) (hereinafter referred to as GPCG-1) After mixing, 475 g (solid content: 10% by weight) of an isomalt hydrate aqueous solution was sprayed and granulated as a binder liquid, and then dried to obtain a granulated product. After sieving to remove aggregates, 212.08 g was weighed from 401.9 g of the obtained granulated product, 10.84 g of L-HPC and 3.23 g of Mg-St were added, and hand-mixed with a polyethylene bag to obtain a mixed product. The obtained mixture was tableted with a rotary tablet press (EX-10, manufactured by Hata Tekko) to obtain plain tablets. 37.69 g of the obtained plain tablet was put into a film coating machine (MINI COATER / DRIER-2, manufactured by CALEVA), and film-coated with a liquid prepared b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
hardnessaaaaaaaaaa
lengthaaaaaaaaaa
Login to View More

Abstract

Provided is a medicinal composition with excellent dissolution stability which contains either 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide (gilteritinib) or a pharmaceutically acceptable salt thereof and further contains a sweetener that reduces the bitterness of gilteritinib and in which the gilteritinib is inhibited from suffering, with the lapse of time, a decrease in dissolution stability due to stresses, e.g., heat and / or humidity, etc. The medicinal composition comprises: gilteritinib or a pharmaceutically acceptable salt thereof; a sweetener; and a saccharide and / or a sugar alcohol.

Description

technical field [0001] The present invention relates to containing 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[( Alkane-4-yl)amino]pyrazine-2-carboxamide or a pharmaceutical composition of a pharmaceutically acceptable salt thereof. Background technique [0002] 6-Ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[( Alkyl-4-yl)amino]pyrazine-2-carboxamide or 6-ethyl-3-({3-methoxy-4-[4-(4-methoxypiperazin-1-yl)piper Pyridine-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter, sometimes referred to as the international common name (INN) Ritinib) is a compound shown in the chemical structural formula of formula (I). It is reported that geritinib or a pharmaceutically acceptable salt thereof, for example, has the ability to inhibit EML4 (Echinoderm microtubule associated protein like-4, echinoderm microtubule binding protein-4)-ALK (Anaplastic lymphoma kinase, anaplastic lymphoma k...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K47/22A61K47/26A61K47/46A61K31/497
CPCA61K31/497A61K9/2018A61K9/2013A61K9/0095A61K9/1694A61K47/22A61K9/2072A61K9/1623
Inventor 佐佐木明彦田中晃宫崎公一高江誓词
Owner ASTELLAS PHARMA INC